未登录

E

Edith M. Heintjes

vrije universiteit amsterdam

H指数:20

被引数:1,508

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries

clinical epidemiology

IF3.2

2020-05-015

OAAI

REAL-WORLD USE OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR (PCSK9-I) ANTIBODIES IN THE NETHERLANDS

ATHEROSCLEROSIS

IF5.7

2019-08-010

PREAI

GLYCAEMIC CONTROL, CARDIOVASCULAR DISEASE AND MORTALITY IN TYPE 2 DIABETES (T2D) PATIENTS IN A REAL LIFE SETTING OVER TIME: POPULATION-BASED DATA FROM THE NETHERLANDS

VALUE IN HEALTH

IF6

2018-10-010

OAAI

Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes

DIABETES OBESITY & METABOLISM

IF5.7

2018-05-298

OAAI

Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study

BMJ OPEN DIABETES RESEARCH & CARE

IF4.1

2018-01-2025

OAAI

Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries

CLINICAL THERAPEUTICS

IF3.6

2017-11-0116

OAAI

Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study

BMJ OPEN DIABETES RESEARCH & CARE

IF4.1

2017-05-2910

OAAI

Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi -database Study

CLINICAL THERAPEUTICS

IF3.6

2017-04-0169

OAAI

Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands

在荷兰的高心血管风险人群中使用调脂疗法和ldl-c目标的实现

CLINICAL THERAPEUTICS

IF3.6

2017-04-0138

OAAI

CLINICAL CHARACTERISTICS AND LDL-CHOLESTEROL MANAGEMENT IN PATIENTS WITH CARDIOVASCULAR EVENT AND/OR DIABETES IN THE NETHERLANDS

ATHEROSCLEROSIS

IF5.7

2016-09-010

PREAI

Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries

BMJ-BRITISH MEDICAL JOURNAL

IF42.7

2016-08-1643

OAAI

FACTORS ASSOCIATED WITH T2DM TREATMENT CHOICE ACROSS EUROPE

VALUE IN HEALTH

IF6

2015-11-012

OAAI

RETRACTED: Exercise therapy for patellofemoral pain syndrome

COCHRANE DATABASE OF SYSTEMATIC REVIEWS

IF9.4

2015-01-2226

OAAI

The 6-year trajectory of non-traumatic knee symptoms (including patellofemoral pain) in adolescents and young adults in general practice: a study of clinical predictors

BRITISH JOURNAL OF SPORTS MEDICINE

IF16.2

2014-11-2735

OAAI

TYPE 2 DIABETES TREATMENT PATTERNS ACROSS EUROPE

VALUE IN HEALTH

IF6

2014-11-013

OAAI

Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010

EUROPEAN HEART JOURNAL

IF35.6

2013-09-17108

OAAI

POPULATION ATTRIBUTABLE RISK OF MICROVASCULAR EVENTS ASSOCIATED WITH HBA1C, BLOOD PRESSURE OR WEIGHT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

VALUE IN HEALTH

IF6

2012-11-010

OAAI

Predictors of persistent complaints after a knee injury in primary care

BRITISH JOURNAL OF GENERAL PRACTICE

IF5.2

2012-08-013

OAAI

POPULATION ATTRIBUTABLE RISK (PAR) OF MACROVASCULAR EVENTS ASSOCIATED WITH HBA1C, BLOOD PRESSURE OR WEIGHT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: EVIDENCE FROM A DUTCH COHORT

VALUE IN HEALTH

IF6

2011-11-014

OAAI

Diagnostic Accuracy of History Taking and Physical Examination for Assessing Anterior Cruciate Ligament Lesions of the Knee in Primary Care

ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION

IF3.7

2010-09-0138

OAAI